Amphetamines for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 12, 2004, Pages

  Nolte, Sue ^a   Wong, David ^b   Latchford, Gary ^c   Boyle, Owen ^d   Anaenugwu, Adaeze ^e  

^a Adult Psychology Service   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Division of Psychiatry ^*  (United Kingdom)

^e Behavioural Sciences Section   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878222068     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004964     Document Type: Review

References (151)

1. Mathew RJ, Wilson WH. Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology 1989;21(3):117-23. [MEDLINE: 90137211]
2. Modell W, Hussar AE. Failure of dextroamphetamine sulphate to influence eating and sleeping patterns in obese schizophrenic patients. JAMA 1965;193(4):275-278.
3. Angrist B, Sanfilipo M, Wolkin A. Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol. Clinical Neuropharmacology 2001;24(3):139-44.
4. Sanfilipo M, Wolkin A, Angrist B, van Kammen DP, Duncan E, Wieland S, Cooper TB, Peselow ED, Rotrosen J. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology 1996;123(2):211-4.
5. Wolkin A, Angrist B, Wolf A, Brodie JD. Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography. Psychopharmacology 1987;92(2):241-6.
6. Angrist B, Sanfilipo M, Wolkin A. Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol. Clinical Neuropharmacology 2001;24(3):139-44.
7. Sanfilipo M, Wolkin A, Angrist B, van Kammen DP, Duncan E, Wieland S, Cooper TB, Peselow ED, Rotrosen J. Amphetamine and negative symptoms of schizophrenia. Psychopharmacology 1996;123(2):211-4.
8. Wolkin A, Sanfilipo M, Angrist B, Duncan E, Wieland S, Wolf AP, Brodie JD, Cooper TB, Laska E, Rotrosen JP. Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology. Biological Psychiatry 1994;36(5):317-25. [MEDLINE: 95086130]
9. Aman MG, Singh NN. Dyskinetic symptoms in profoundly retarded residents following neuroleptic withdrawal and during methylphenidate treatment. Journal of Mental Deficiency Research 1985;29(2):187-95. [MEDLINE: 85293054]
10. Angrist B, Shopsin B, Gershon S. Comparative psychomimetic effects of stereoisomers of amphetamine. Nature 1971;234(5325):152-3.
11. Angrist B, Lee HK, Gershon S. The antagonism of amphetamine induced symptomatology by a neuroleptic. American Journal of Psychiatry 1974;131(7):817-9.
12. Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology 1980;72(1):17-9.
13. Angrist B, Rotrosen J, Gershon S. Responses to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology 1980;67(1):31-8.
14. Angrist B, Sanfilipo M, Wolkin A. Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol. Clinical Neuropharmacology 2001;24(3):139-44.
15. Angrist B, Peselow E, Rubinstein M, Corwin J, Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology 1982;78(2):128-130.
16. Angrist B, Sanfilipo M, Wolkin A. Cardiovascular effects of 0.5 milligrams per kilogram oral d-amphetamine and possible attenuation by haloperidol. Clinical Neuropharmacology 2001;24(3):139-44.
17. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M. Evaluation of a motivational interview for substance use within psychiatric inpatient services. Unpublished 2002 2002. [MEDLINE: 77167227]
18. Bilder RM, Lieberman JA, Kim Y, Alvir JM. Methylphenidate and neuroleptic effects on oral word production in schizophrenia. Neuropsychiatry Neuropsychology and Behavioral Neurology 1992;5(4):262-71.
19. Broadhurst A. Experimental studies of the mental speed of schizophrenics. I. Effects of a stimulant and a depressant drug. Journal of Mental Science (British Journal of Psychiatry from 1963) 1958;104:1123-9.
20. Brown ES, Nejtek VA, Perantie DC. Neuroleptics and quetiapine in psychiatric illnesses with comorbid stimulant abuse. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S157.
21. Buchanan RW, Carpenter WT, Kirkpatrick B, Bryant N, Bustillo J. Dopamine agents for the treatment of the negative symptoms of schizophrenia. Schizophrenia Research 1995;15(1,2):144. [MEDLINE: 75028515]
22. Campbell M, Fish B, Shapiro T, Floyd A. Acute responses of schizophrenic children to a sedative and a "stimulating" neuroleptic: A pharmacologic yardstick. Current Therapeutic Research 1972;14(12):759-66.
23. Campbell M. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Current Therapeutic Research 1976;19(1):70-86.
24. Campbell M, Cohen IL, Small AM. Drugs in aggressive behavior. Journal of the American Academy of Child Psychiatry 1982;21(2):107-17.
25. Carpenter MD, Winsberg BG, Camus LA. Methylphenidate augmentation therapy in schizophrenia. Journal of Clinical Psychopharmacology 1992;12(4):273-5. [MEDLINE: 92407115]
26. Cassady SL, Adami H, Moran M, Kunkel R, Thaker GK. Spontaneous dyskinesia in subjects with schizophrenia spectrum personality. American Journal of Psychiatry 1998;155(1):70-5. [MEDLINE: 98094915]
27. Cassady SL, Adams HM, Kunkel RS, Sherr JD, Moran MJ, Thaker GK. Lack of response to amphetamine in schizophrenia spectrum personality. Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA). 1999:306. [MEDLINE: 81175504]
28. Cassady SL, Thaker GK, Adami H, Moran M, Zhou Y, Kunkle R. Stereotypic response to amphetamine in spectrum personality. Schizophrenia Research 1995;15(1,2):145. [MEDLINE: 75028515]
29. Cesarec Z, Eberhard G, Nordgren L. A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. A clinical and experimental-psychological study. Acta Psychiatrica Scandinavica Supplementum 1974;249:65-77. [MEDLINE: 75029586]
30. Chouinard G, Annable L, Young SN, Sourkes TL. A controlled study of tryptophan-benserazide in schizophrenia. Communications in Psychopharmacology 1978;2(1):21-31. [MEDLINE: 85175264]
31. Clausen J, Fisher S. Effects of amphetamine and barbiturate on body experience. Psychosomatic Medicine 1973;35(5):390-405. [MEDLINE: 75047217]
32. Corr PJ, Kumari V. Individual differences in mood reactions to d-amphetamine: a test of three personality factors. Journal of Psychopharmacology 2000;14(4):371-7. [MEDLINE: 21039322]
33. Costello CG. The effects of depressant and stimulant drugs on the relationship between reaction time and stimulus light intensity. British Journal of Social and Clinical Psychology 1964;3(1):1-5.
34. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. Journal of Neuroscience 1991;11(7):1907-17. [MEDLINE: 91294846]
35. Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. American Journal of Psychiatry 1991;148(1):78-84. [MEDLINE: 91083132]
36. Llewellyn B, Bigelow MD, Goldberg TE, Daniel DG, Klienman JE. Acute amphetamine effect on neuropsychological testing in chronic schizophrenia. Schizophrenia Reseach (Winter Workshop on Schizophrenia, 1988, Badagastein, Austria). 1988, issue 2-3:249-50.
37. Fann WE, Davis JM, Wilson IC. Methylphenidate in tardive dyskinesia. American Journal of Psychiatry 1973;130(8):922-4.
38. Fish B, Shapiro T, Campbell M. Long-term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. American Journal of Psychiatry 1966;123(1):32-39.
39. Forrest GL, Bortner TW, Bakker CB. The role of personality variables in response to chlorpromazine, dextroamphetamine and placebo. Journal of Psychiatric Research 1967;5:281-8. [MEDLINE: 68129031]
40. Gefvert O, Lundberg T, Hagstrom P, Lindstrom L, Sonesson C, Waters N, Carlsson A, Tedroff J. Dopamine stabilizers;pharmacokinetics, antipsychotic effects and safety. International Journal of Neuropsychopharmacology (Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada). 2002, issue Suppl 1:S176.
41. Gillin JC, van Kammen DP, Bunney WE Jr. Pimozide attentuates d-amphetamine-induced sleep changes in man. Life Sciences 1978;22(20):1805-10. [MEDLINE: 78222494]
42. Gray NS, Pickering AD, Gray JA. Increased schizotypy scores in normal subjects following the oral administration of D-amphetamine. Schizophrenia Research 1996;18(2,3):119. [MEDLINE: 75028515]
43. Gross G, Bailey P, Bialojan S, Garcia Ladona FJ, Geyer M, Greger G, Luthringer R, P Macher JAU, Needham P, Müller B, Rendenbach Steiner. LU 111995, a dopamine D4 AND 5 hydroxytryptamine 2A antagonist: pharmacological characterisation and first clinical experience. 11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris, France. 1998.
44. Honigfeld G, Patin J, Singer J. Clozapine - antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy 1984;1(2):77-97. [MEDLINE: 91083132]
45. Janowsky DS, el Yousef MK, Davis JM, Sekerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Archives of General Psychiatry 1973;28(2):185-91. [MEDLINE: 73084703]
46. Janowski DS, Davis JM, El Yousef MK. Proceedings: effect of intravenous d amphetamine, l amphetamine and methylphenidate in schizophrenics. Psychopharmacology Bulletin 1974;10(3):15-24. [MEDLINE: 75022670]
47. Janowsky DS, Davis JM. Dopamine, psychomotor stimulants, and schizophrenia: effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. Advances in Biochemical Psychopharmacology 1974;12:317-23. [MEDLINE: 75028515]
48. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms. Archives of General Psychiatry 1976;33(3):304-8. [MEDLINE: 76159941]
49. Janowsky DS, Leichner P, Clopton P, Judd LL, Parker D, Huey L. Comparison of oral and intravenous methylphenidate. Psychopharmacology Berlin 1978;59(1):75-8. [MEDLINE: 79084289]
50. Jauhar P, Suddle A, Skelton F, Smith G. The prevalence of substance abuse and dual diagnosis within an in-patient population serving the end of Glasgow. 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001, issue Suppl. 1.
51. Kopell BS, Wittner WK. The effects of chlorpromazine and methamphetamine on visual signal-from-noise detection. Journal of Nervous and Mental Disease 1968;147:418-24. [MEDLINE: 69011975]
52. Kornetsky C. Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Archives of General Psychiatry 1976;33(12):1425-8. [MEDLINE: 77064771]
53. Kroner S, Schall U, Ward PB, Sticht G, Banger M, Haffner HT, Catts SV. Effects of prepulses and d amphetamine on performance and event related potential measures on an auditory discrimination task. Psychopharmacology Berlin 1999;145(2):123-32. [MEDLINE: 99390953]
54. Krystal JH, D'Souza DC, Belger A, Cassello K, Madonick S, Sernyak M, Abi-Saab W. Amphetamine pretreatment reduces attention deficits, but not psychosis, produced by ketamine, produced in healthy human subjects. Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA). 1999:309-10.
55. Krystal JH, D'Souza DC, Belger A, Madonick S, Cossello K. Ketamine and amphetamine interactions in healthy humans: further insights into glutamate dopamine interactions. Schizophrenia Research 2000;235(1):235. [MEDLINE: 79084289]
56. Kumari V, Corr PJ, Mulligan OF, Cotter PA. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man. Psychopharmacology 1997;129(3):271-6.
57. Kumari V, Corr PJ, Mulligan OF, Cotter PA, Checkley SA, Gray JA. Effects of acute administration of D-amphetamine and haloperidol on procedural learning in man. Schizophrenia Research (6th International Congress on Schizophrenia Research; 1997 Apr 12-16; Colorado, USA). 1997, issue 1+2 (special):110. [MEDLINE: 77064771]
58. Kumari V, Mulligan OF, Cotter PA, Poon L, Toone BK, Checkley SA, Gray JA. Effects of single oral administrations of haloperidol and d amphetamine on prepulse inhibition of the acoustic startle reflex in healthy male volunteers. Behavioural Pharmacology 1998;9(7):567-76. [MEDLINE: 99079075]
59. Lahti AC, Weiler MA, Michaelidis T, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25(4):455-67.
60. Laurelle M, Abi-Dargham A, Van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS. Single photon emission computerised tomography imaging of amphetamine induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 1996;93(17):9235-9240.
61. Leszek J, Inglot AD, Cantell K, Wasik A. Natural human leukocyte interferon in the treatment of schizophrenia. European Journal of Psychiatry 1991;5(1):55-63.
62. Levy DL, Smith M, Robinson D, Jody D, Lerner G, Alvir J, Geisler SH, Szymanski SR, Gonzalez A, Mayerhoff DI. Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biological Psychiatry 1993;34(8):507-14. [MEDLINE: 94100319]
63. Lieberman JA, Alvir J, Geisler S, Ramos Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994;11(2):107-18. [MEDLINE: 95142895]
64. Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B. Methylphenidate challenge as a predictor of relapse in schizophrenia. American Journal of Psychiatry 1984;141(5):633-8. [MEDLINE: 84176244]
65. Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos Lorenzi J. Prediction of relapse in schizophrenia. Archives of General Psychiatry 1987;44(7):597-603. [MEDLINE: 87270065]
66. Lieberman JA, Kane JM, Sarantakos S, Gadaletta D, Woerner M, Alvir J, Ramos Lorenzi J. Prediction of relapse in schizophrenia. Psychopharmacology Bulletin 1986;22(3):845-53. [MEDLINE: 87092873]
67. Malaspina D, Colemann EA, Quitkin M, Amador XF, Kaufmann CA, Gorman JM, Sackeim HA. Effects of pharmacologic catecholamine manipulation on smooth pursuit eye movements in normals. Schizophrenia Research 1994;13(2):151-9. [MEDLINE: 95078210]
68. McCartan D, Bell R, Green JF, Campbell C, Trimble K, Pickering A, King DJ. The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. Journal of Psychopharmacology 2001;15(2):96-104.
69. Overall JE, Hollister LE, Pokorny AD, Casey JF. Drug therapy in depressions: Controlled evaluation of impramine, isocarboxazide, dextroamphetamine-amobarbital, and placebo. Clincal Pharmacology and Therapeutics 1961;3(1):16-22.
70. Pandurangi AK, Goldberg SC, Brink DD, Hill MH, Gulati AN, Hamer RM. Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia. Biological Psychiatry 1989;25(2):207-14. [MEDLINE: 89194262]
71. Perry W, McDougall A, Schaible D, Sprock J. Amphetamines on Rorschach measures in normal subjects. Journal of Personality Assessment 1995;64(3):456-65. [MEDLINE: 95280232]
72. Pfeiffer CC, Goldstien L, Murphree HB, Sugerman AA. Time-series frequency analysis and electrogenesis of the EEG's of normals and psychotics before and after drugs. American Journal of Psychiatry 1965;122:1147-55.
73. Rappaport M. Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. Journal of Nervous and Mental Disease 1968;146:404-11. [MEDLINE: 68276064]
74. Robinson DG, Mayerhoff D, Alvir J, Cooper T. Mood responses of remitted schizophrenics to methylphenidate infusion. Psychopharmacology 1991;16(2):247-52.
75. Schulz CS, van Kammen DP, Pickar D, Cohen MR, Naber D. Response of plasma beta endorphin immunoreactivity to d amphetamine and placebo in schizophrenic patients. Psychiatry Research 1982;7(2):171-8. [MEDLINE: 83065835]
76. Sharma RP, Javaid JI, Pandey GN, Easton M, Davis JM. Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. Psychiatry Research 1990;32(1):9-17. [MEDLINE: 90272848]
77. Sharma RP, Javaid JI, Pandey GN, Janicak PG, Davis JM. Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients. Biological Psychiatry 1991;30(5):459-66. [MEDLINE: 92032138]
78. Sherr JD, Cassday SL, Ross DR, Thaker GK. Amphetamine challenge asymmetrically disrupts eye movements in schizophrenia spectrum personality. Schizophrenia Research (Abstracts of The 7th International Congress on Schizophrenia Research; 1999 Apr 17-21; Santa Fe, USA). 1999:315.
79. Smith RC, Tamminga C, Davis JM. Effect of apomorphine on schizophrenic symptoms. Journal of Neural Transmission 1977;40(2):171-6. [MEDLINE: 77167227]
80. Soederholm S, Viukari NMA, Rimon R. Psychotropic actions of pyrovalerone, placebo, and environmental therapy and role of mental state in patients detained in a mental hospital on a court order (German) [Die psychotrope Wirkung von Pyrovalerone (F-1983), Placebo, Milieutherapie und psychischer Zustand bei gerichtspsychiatrischen Patienten]. Nervenarzt 1976;47(2):88-93.
81. StJean A, Sterlin C, Noe W, Ban TA. Clinical studies with propericiazine (RP. 8909). Diseases of the Nervous System 1967;28(8):526-31. [MEDLINE: 68001405]
82. Strakowski SM, Sax KW, Setters MJ, Stanton SP, Keck PE Jr. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: Implications for a sensitization model of psychosis in humans. Biological Psychiatry 1997;42(9):749-55. [MEDLINE: 98006671]
83. van Kammen DP, Bunney WE Jr, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, Rayner JN. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. American Journal of Psychiatry 1982;139:991-7. [MEDLINE: 82228213]
84. van Kammen DP, Bunney WE, Docherty JP, Jimerson DC, Post RM, Siris P, Ebert M, Gillin JC. Amphetamine-induced catecholamine activation in schizophrenia and depression: behavioral and physiological effects. Advances in Biochemical Psychopharmacology 1977;16:655-9. [MEDLINE: 77239321]
85. van Kammen DP, Docherty JP, Bunney WE Jr. Prediction of early relaspe after pimozide discontinuation by response to d-amphetamine during pimozide tretament. Biological Pyschiatry 1982;17(2):233-242.
86. van Kammen DP, Docherty JP, Marder SR, Rayner JN, Bunney WE Jr. Long-term pimozide pretreatment differentially affects behavioural responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia. Archives of General Psychiatry 1982;39(3):275-281.
87. van Kammen DP, Docherty JP, Marder SR, Schultz SC, Dalton L, Bunney WE Jr. Antipsychotic effects of pimozide in schizophrenia. Treatment reponse prediction with acute dextroamphetamine response. Archives of General Psychiatry 1982;39(3):261-266.
88. van Kammen DP, Docherty JP, Marder SR, Schulz SC, Bunney WE Jr. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients. Archives of General Psychiatry 1980;37(3):287-90. [MEDLINE: 80152629]
89. van Kammen DP, Docherty JP, Marder SR, Siris SG, Bunney WE Jr. d-Amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment. Life Sciences 1978;23(14):1487-92. [MEDLINE: 79052260]
90. van Kammen DP, Docherty JP, Rayner JN, Bunney WE Jr. Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients. Psychiatry Research 1981;4(3):313-325.
91. van Kammen DP, Docherty JP, Marder SR. Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia. Psychopharmacology 1985;87(1):111-5. [MEDLINE: 98006671]
92. van Kammen DP, Boronow JJ. Dextro-amphetamine diminishes negative symptoms in schizophrenia. International Clinical Psychopharmacology 1988;3(2):111-21. [MEDLINE: 88285619]
93. Witton K. Clinical observations on ritalin HCL (methylphenidylacetate) injectable, multiple dose vial. American Journal of Psychiatry 1960;117:156-7. [MEDLINE: 82228213]
94. Zahn TP, Rapoport JL, Thompson CL. Autonomic effects of dextroamphetamine in normal men: implications for hyperactivity and schizophrenia. Psychiatry Research 1981;4(1):39-47. [MEDLINE: 81175504]
95. Zemishlany Z, Aizenberg D, Weizman A. Effects of agents active at the dopaminergic system on sexual function. 9th Congress of the Association of European Psychiatrists; 1998 Sep 20-24; Copenhagen, Denmark. 1998.
96. Zylberman I, Javitt DC, Zukin SR. NMDA receptor augmentation therapy in schizophrenia. Schizophrenia Research 1995;15(1,2):171.
97. Zylberman I, Javitt DC, Zukin SR. Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia. Annals of the New York Academy of Sciences 1995;757:487-491.
98. Barch DM, Carter CS, Braver TS, Cohen JD. The effects of D-amphetamine on working memory and language deficits in schizophrenia. Schizophrenia Research (6th International Congress on Schizophrenia Research; 1997 Apr 12-16; Colorado, USA). 1997, issue 1+ 2 (special):129.
99. Casey JF, Hollister LE, Klett CJ, Lasky JJ, Caffey EM. Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine. American Journal of Psychiatry 1961;117:997-1003. [MEDLINE: 92407115]
100. Filipova M, David I, Filip V, Krejcova H, Mladkova I. Effect of a single administration of amphetamine on vestibular caloric reaction in healthy volunteers [Vliv jednorazoveho podani amfetaminu na vestibularni kalorickou reakci zdravych lidi]. Ceskoslovenska Otolaryngologie 1978;27(6):352-4. [MEDLINE: 79084289]
101. Os'makova EI. Use of psychological methods for studying the particular psychotropic action of various psychopharmacologic drugs [Primenenie psikhologicheskikh metodik dlia issledovaniia sobstvenno psikhotropnogo deistviia nekotorykh psikhofarmakologicheskikh sredtsv]. Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova 1972;72(11):1705-8. [MEDLINE: 73197279]
102. Abrams R, Taylor MA. A rating scale for emotional blunting. American Journal of Psychiatry 1978;135:225-229.
103. Altman DG, Bland JM. Detecting skewness from summary information. British Medical Journal 1996;313:1200.
104. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. The Lancet 1987;2 8574:1483-1486.
105. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington D.C: American Psychiatric Association, 1980.
106. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM III-R). American Psychiatric Association. Washington D.C.: American Psychiatric Association, 1987.
107. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup Df. Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-9.
108. Blanchard JJ, Brown SA, Horan WP, Sherwood AR. Substance use disorders in schizophrenia. Review, integration and proposed model. Clinical Psychology Review 2000;20:207-334.
109. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. British Medical Journal 315;7108:600.
110. Bowen J, Hirsch S. Recruitment rates and factors affecting recruitment for a trial of a putative anti-psychotic agent in the treatment of schizophrenia. Human Psychopharmacology 1992;7:337-341.
111. Bowen J, Barnes TRE. The clinical characteristics of schizophrenic patients consenting or not consenting to a placebo controlled trial of anti-psychotic medication. Human Psychopharmacology 1994;9:423-433.
112. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Threats to the applicability of randomised trials: exclusions and selective participation. Journal of Health Services Research 1999;4:112-121.
113. Clarke M, Oxman AD. Cochrane Reviewers' Handbook 4.2.0. Cochrane Database of Systematic Reviews 2003, Issue 2.
114. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance abuse and schizophrenia: effects on symptoms but not on neurocognitive function. Journal of Clinical Psychiatry 1991;52:26-30.
115. Cleophas TJ. Carry-over biases in clinical pharmacology. European Journal of Clinical Chemistry & Clinical Biochemistry 1993;31:803-809.
116. Cohen LJ, Test MA, Brown RJ. Suicide and schizophrenia: data from a prospective community treatment study. Americal Journal of Psychiatry 1990;147:602-607.
117. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials III: The issue of carry-over. Statistics in Medicine 2002;21:2161-2173.
118. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials I: Continuous outcomes. Statistics in Medicine 2002;21:2131-2144.
119. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 1992;7(6):623-629.
120. Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Hospital and Community Psychiatry 1989;40:1041-1046.
121. Drake RE, Osher DL, Noordsy SC, Hurlbut GB, Teague GB, Beaudett MS. Diagnosis of alcohol disorders in schizophrenia. Schizophrenia Bulletin 1990;16:57-67.
122. Drake RE, Wallach MA, Teague GB, Freeman DH, Paskus TS, Clark TA. Housing instability and homelessness among rural schizophrenic patients. American Journal of Psychiatry 1991;148:330-336.
123. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001359.pub2]
124. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-634.
125. Elbourne D, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-149.
126. Evers A. Improving test quality in the Netherlands: Results of 18 years of test ratings. International Journal of Testing 2001;1:137-153 137-153.
127. Gilbody SM, Petticrew M. Rational decision-making in mental health: the role of systematic reviews. Journal of Mental Health Policy and Economics 1999;2:99-106.
128. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. Americal Journal of Epidemiology 1999;149:876-883.
129. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised edition. US Department of Health, Education, and Welfare., 1976.
130. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD000440]
131. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-2.
132. Jadad AR. Randomised Controlled Trials. London UK, BMJ Books., 1998.
133. Juni P, Altman DG, Egger M. Systematic reviews in healthcare. Assessing the quality of controlled clinical trials. British Medical Journal 2001;323:42-46.
134. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry 1985;142:1259-1264.
135. Khantzian EJ. The self-medication hypothesis of substance abuse disorders: a reconsideration and recent applications. Harvard Review of Psychiatry 1987;4:231-244.
136. Lieberman JA, Jody D, Greisler S, Vital-Herne J, Alvir JMJ, Walsleben J, Woerner MG. Treatment outcome of first episode schizophrenia. Psychopharmacology Bulletin 1989;25:92-96.
137. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-252.
138. Mazzocato C, Bruera E. Clinical research in palliative care: choice of trial design. Palliative Medicine 2001;15:261-264.
139. McMonagle T, Sultana A. Token economy for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001473]
140. Moher D, Schultz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Journal of the American Medical Association, 2001;285:1987-1991.
141. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatrica Scandinavica 1992;85:48-55.
142. Olson CM, Drummond R, Cook D, Dickerson K, Flanagin A, Hogan JW, Zhu Q, Reiling J, Pace B. Publication bias in editorial decision making. Journal of the American Medical Association 2002;287:2825-2828.
143. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:709-712.
144. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Academy 1990;264:2511-2518.
145. Richens A. Proof of efficacy trials: cross-over versus parallel-group. Epilepsy Research 2001;45:43-47.
146. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. Journal of Nervous and Mental Disease 1987;175:641-52.
147. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408-412.
148. Seibyl JP, Satel SL, Anthony D, Sothwick SM, Krystal JH, Charney DS. Effects of cocaine on hospital course in schizophrenia. The Journal of Nervous and Mental Disease 1993;181:31-37.
149. Senn S. Cross-over trials in clinical research: Chichester UK. John Wiley & Sons Ltd., 1993.
150. Senn S. Clinical cross-over trials in phase I. Statistical Methods in Medical Research 1999;8:263-278.
151. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978;35(6):773-82.